197 related articles for article (PubMed ID: 19323612)
21. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
[TBL] [Abstract][Full Text] [Related]
22. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
23. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
24. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL
Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796
[TBL] [Abstract][Full Text] [Related]
25. Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Heller W; Cruz M; Bhagat YR; De Leon JM; Felix C; Villanueva L; Hollander DA; Jensen H
J Ocul Pharmacol Ther; 2014 Dec; 30(10):815-22. PubMed ID: 25244402
[TBL] [Abstract][Full Text] [Related]
26. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
Morris TW; Gearinger LS; Usner DW; Paterno MR; Decory HH; Comstock TL; Haas W
Clin Ophthalmol; 2011; 5():1359-67. PubMed ID: 22034555
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
29. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Hwang DG; Schanzlin DJ; Rotberg MH; Foulks G; Raizman MB;
Br J Ophthalmol; 2003 Aug; 87(8):1004-9. PubMed ID: 12881345
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
31. A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
Am J Ophthalmol; 2020 Jul; 215():56-65. PubMed ID: 32222367
[TBL] [Abstract][Full Text] [Related]
32. Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Majmudar PA; Clinch TE
Cornea; 2014 May; 33(5):457-62. PubMed ID: 24637269
[TBL] [Abstract][Full Text] [Related]
33. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2018 Oct; 194():7-15. PubMed ID: 29787732
[TBL] [Abstract][Full Text] [Related]
34. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Parekh JG; Newsom TH; Nielsen S
J Cataract Refract Surg; 2012 Oct; 38(10):1864-7. PubMed ID: 22999608
[No Abstract] [Full Text] [Related]
35. Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods.
Tótoli EG; Salgado HRN
Crit Rev Anal Chem; 2018 Mar; 48(2):132-142. PubMed ID: 29345957
[TBL] [Abstract][Full Text] [Related]
36. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
37. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
Granet DB; Dorfman M; Stroman D; Cockrum P
J Pediatr Ophthalmol Strabismus; 2008; 45(6):340-9. PubMed ID: 19043945
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis.
Jauch A; Fsadni M; Gamba G
Graefes Arch Clin Exp Ophthalmol; 1999 Sep; 237(9):705-13. PubMed ID: 10447643
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
40. A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.
Yee RW; Tepedino M; Bernstein P; Jensen H; Schiffman R; Whitcup SM;
Curr Med Res Opin; 2005 Mar; 21(3):425-31. PubMed ID: 15811211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
